Abstract
Alzheimer’s disease involves extracellular β-amyloid accumulation and intracellular phosphorylated tau aggregates, with higher disease prevalence and neuropathological burden in aging females. While tau phosphorylation contributes to tau pathology, other modifications, such as acetylation, also promote aggregation. Aging disrupts proteostasis, in part through acetylation, a post-translational modification affecting protein function and stability; however, its role in sex-specific tauopathy remains unclear. This study investigated acetylation in an age-, sex-specific manner across presymptomatic (3–5 months), progressive (11–14 months), and advanced (> 16 months) stages of tauopathy in htau mice using immunoassays. In females, cortical tau K174 acetylation increased with age and disease progression, correlating with tau accumulation. In males, tau phosphorylation increased without acetylation changes, indicating sex-specific regulation. Free ubiquitin, a marker of impaired proteasomal degradation, rose with age in both females and males. Autophagy markers also showed marked age-related decline in both sexes, contributing to tau accumulation. Increased mTOR expression in aged mice further suggested mTOR-driven autophagy inhibition. These findings suggest that aging-related disruptions in brain acetylation are associated with accelerated tau pathology, with females potentially being more vulnerable due to elevated tau acetylation coinciding with impaired protein degradation pathways.
Data availability
The data supporting the findings of this study are available in Supplementary Materials. Supplementary Tables S1–S3 provide an overview of the datasets and protein-level summary statistics, and Supplementary Figures S1–S10 include immunohistology images and full-length representative immunoblots.
References
Chandrashekar, D. V. et al. Alcohol as a Modifiable Risk Factor for Alzheimer’s Disease-Evidence from Experimental Studies. Int. J. Mol. Sci., 24(11), 9492 (2023).
Sullivan, E. V. & Pfefferbaum, A. Alcohol use disorder: neuroimaging evidence for accelerated aging of brain morphology and hypothesized contribution to age-related dementia. Alcohol 107, 44–55 (2023).
Bostrand, S. M. K. et al. Associations between alcohol use and accelerated biological ageing. Addict. Biol. 27 (1), e13100 (2022).
Ferretti, M. T. et al. Sex differences in Alzheimer disease: the gateway to precision medicine. Nat. Rev. Neurol. 14 (8), 457–469 (2018).
Livingston, G. et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 404 (10452), 572–628 (2024).
Polanco, J. C. et al. Amyloid-beta and tau complexity: towards improved biomarkers and targeted therapies. Nat. Rev. Neurol. 14 (1), 22–39 (2018).
Bejanin, A. et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain 140 (12), 3286–3300 (2017).
Samudra, N. et al. Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues. J. Clin. Investig. 133(12). (2023).
Cruz, E. et al. Proteostasis as a fundamental principle of Tau immunotherapy. Brain 148 (1), 168–184 (2025).
Parra Bravo, C., Naguib, S. A. & Gan, L. Cellular and pathological functions of tau. Nat. Rev. Mol. Cell. Biol. 25 (11), 845–864 (2024).
Kyalu Ngoie Zola, N. et al. Specific post-translational modifications of soluble tau protein distinguishes Alzheimer’s disease and primary tauopathies. Nat. Commun. 14 (1), 3706 (2023).
Wesseling, H. et al. Tau PTM profiles identify patient heterogeneity and stages of Alzheimer’s disease. Cell 183 (6), 1699–1713e13 (2020).
Goedert, M. et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3 (4), 519–526 (1989).
Spillantini, M. G. et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA 95 (13), 7737–7741 (1998).
Capano, L. S. et al. Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neurons. Cell. Stem Cell. 29 (6), 918–932e8 (2022).
Bachmann, S. et al. Differential effects of the six human TAU isoforms: somatic retention of 2 N-TAU and increased microtubule number induced by 4R-TAU. Front. Neurosci. 15, 643115 (2021).
Lee, G., Neve, R. L. & Kosik, K. S. The microtubule binding domain of tau protein. Neuron 2 (6), 1615–1624 (1989).
Zheng, H. et al. The enigma of tau protein aggregation: mechanistic insights and future challenges. Int. J. Mol. Sci. 25(9), 4969 (2024).
Cook, C. et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet. 23 (1), 104–116 (2014).
Cohen, T. J. et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2, 252 (2011).
Min, S. W. et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67 (6), 953–966 (2010).
Weaver, C. L. et al. Conformational change as one of the earliest alterations of tau in Alzheimer’s disease. Neurobiol. Aging. 21 (5), 719–727 (2000).
Gotz, J. et al. What renders TAU toxic. Front. Neurol. 4, 72 (2013).
Maeda, S. et al. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer’s disease. Neurosci. Res. 54 (3), 197–201 (2006).
Combs, B. et al. Frontotemporal lobar dementia mutant tau impairs axonal transport through a protein phosphatase 1gamma-dependent mechanism. J. Neurosci. 41 (45), 9431–9451 (2021).
Rawat, P. et al. Phosphorylated tau in Alzheimer’s disease and other tauopathies. Int. J. Mol. Sci. 23(21), 12841 (2022).
Giannakopoulos, P. et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology 60 (9), 1495–1500 (2003).
Hanger, D. P., Anderton, B. H. & Noble, W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15 (3), 112–119 (2009).
Fitzpatrick, A. W. P. et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature 547 (7662), 185–190 (2017).
Min, S. W. et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med. 21 (10), 1154–1162 (2015).
Kim, M. S. et al. Tau acetylation at K280 regulates tau phosphorylation. Int. J. Neurosci. 133 (12), 1394–1398 (2023).
Carlomagno, Y. et al. An acetylation-phosphorylation switch that regulates tau aggregation propensity and function. J. Biol. Chem. 292 (37), 15277–15286 (2017).
Julien, C. et al. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J. Neuropathol. Exp. Neurol. 68 (1), 48–58 (2009).
Ding, H., Dolan, P. J. & Johnson, G. V. Histone deacetylase 6 interacts with the microtubule-associated protein tau. J. Neurochem. 106 (5), 2119–2130 (2008).
Tracy, T. E. & Gan, L. Acetylated tau in Alzheimer’s disease: an instigator of synaptic dysfunction underlying memory loss: Increased levels of acetylated tau blocks the postsynaptic signaling required for plasticity and promotes memory deficits associated with tauopathy. Bioessays, 39(4) (2017). https://doi.org/10.1002/bies.201600224
Tracy, T. E. et al. Acetylated tau obstructs KIBRA-mediated signaling in synaptic plasticity and promotes tauopathy-related memory loss. Neuron 90 (2), 245–260 (2016).
Shin, M. K. et al. Reducing acetylated tau is neuroprotective in brain injury. Cell 184 (10), 2715–2732e23 (2021).
Duff, K. et al. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol. Dis. 7 (2), 87–98 (2000).
Tucker, K. L., Meyer, M. & Barde, Y. A. Neurotrophins are required for nerve growth during development. Nat. Neurosci. 4 (1), 29–37 (2001).
Combs, B., Hamel, C. & Kanaan, N. M. Pathological conformations involving the amino terminus of tau occur early in Alzheimer’s disease and are differentially detected by monoclonal antibodies. Neurobiol. Dis. 94, 18–31 (2016).
Horowitz, P. M. et al. N-terminal fragments of tau inhibit full-length tau polymerization in vitro. Biochemistry 45 (42), 12859–12866 (2006).
Ward, S. M. et al. TOC1: characterization of a selective oligomeric tau antibody. J. Alzheimers Dis. 37 (3), 593–602 (2013).
Patterson, K. R. et al. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J. Biol. Chem. 286 (26), 23063–23076 (2011).
Ito, D. et al. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res. Mol. Brain Res. 57 (1), 1–9 (1998).
Kanazawa, H. et al. Macrophage/microglia-specific protein Iba1 enhances membrane ruffling and Rac activation via phospholipase C-gamma-dependent pathway. J. Biol. Chem. 277 (22), 20026–20032 (2002).
Xia, Y., Prokop, S. & Giasson, B. I. Don’t phos over tau: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies. Mol. Neurodegener. 16 (1), 37 (2021).
Malia, T. J. et al. Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8. Proteins 84 (4), 427–434 (2016).
Dengler-Crish, C. M., Smith, M. A. & Wilson, G. N. Early evidence of low bone density and decreased serotonergic synthesis in the dorsal raphe of a tauopathy model of Alzheimer’s disease. J. Alzheimers Dis. 55 (4), 1605–1619 (2017).
Wiera, G. et al. Integrins bidirectionally regulate the efficacy of inhibitory synaptic transmission and control GABAergic plasticity. J. Neurosci. 42 (30), 5830–5842 (2022).
Searle, S. R., Speed, F. M. & Milliken, G. A. Population marginal means in the linear model: an alternative to least squares means. Am. Stat. 34 (4), 216–221 (1980).
Lenth, R. & Piaskowski, J. emmeans: Estimated Marginal Means, aka Least-Squares Means (2025). https://doi.org/10.32614/CRAN.package.emmeans.
Andorfer, C. et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86 (3), 582–590 (2003).
Covarrubias, A. J. et al. NAD(+) metabolism and its roles in cellular processes during ageing. Nat. Rev. Mol. Cell. Biol. 22 (2), 119–141 (2021).
Eftekhari, A., Sabir, U. & Kasumov, T. The role of lysine acetylation in metabolic sensing and proteostasis. Pharmacol. Ther. 274, 108908 (2025).
Lee, M. J., Lee, J. H. & Rubinsztein, D. C. Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog Neurobiol. 105, 49–59 (2013).
Sadoul, K. et al. Regulation of protein turnover by acetyltransferases and deacetylases. Biochimie 90 (2), 306–312 (2008).
Jahngen, J. H. et al. Aging and cellular maturation cause changes in ubiquitin-eye lens protein conjugates. Arch. Biochem. Biophys. 276 (1), 32–37 (1990).
Dudek, E. J. et al. Ubiquitin proteasome pathway-mediated degradation of proteins: effects due to site-specific substrate deamidation. Investig. Ophthalmol. Vis. Sci. 51 (8), 4164–4173 (2010).
Otoda, T. et al. Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver. Diabetes 62 (3), 811–824 (2013).
Hara, T. et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441 (7095), 885–889 (2006).
Russell, R. C. et al. ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. Nat. Cell. Biol. 15 (7), 741–750 (2013).
Jung, C. H. et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol. Biol. Cell. 20 (7), 1992–2003 (2009).
Morita, T. & Sobue, K. Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. J. Biol. Chem. 284 (40), 27734–27745 (2009).
Egan, D. F. et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331 (6016), 456–461 (2011).
Kim, J. et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell. Biol. 13 (2), 132–141 (2011).
Shaw, R. J. et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA 101 (10), 3329–3335 (2004).
Hutton, M. et al. Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393 (6686), 702–705 (1998).
Editorial 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 17 (3), 327–406 (2021).
Lasagna-Reeves, C. A. et al. Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49 (47), 10039–10041 (2010).
Lasagna-Reeves, C. A. et al. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol. Neurodegener. 6, 39 (2011).
Lopez-Lee, C. et al. Mechanisms of sex differences in Alzheimer’s disease. Neuron 112 (8), 1208–1221 (2024).
Waddell, A. R., Huang, H. & Liao, D. CBP/p300: critical co-activators for nuclear steroid hormone receptors and emerging therapeutic targets in prostate and breast cancers. Cancers (Basel) 13 (12). (2021).
Haj-Yahya, M. & Lashuel, H. A. Protein semisynthesis provides access to tau disease-associated post-translational modifications (PTMs) and paves the way to deciphering the tau PTM code in health and diseased states. J. Am. Chem. Soc. 140 (21), 6611–6621 (2018).
Shang, D. et al. Sex differences in autophagy-mediated diseases: toward precision medicine. Autophagy 17 (5), 1065–1076 (2021).
Chen, X. et al. Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy. Mol. Neurodegener. 15 (1), 2 (2020).
Congdon, E. E. Sex differences in autophagy contribute to female vulnerability in Alzheimer’s disease. Front. Neurosci. 12, 372 (2018).
Caccamo, A. et al. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer’s disease and other tauopathies. Aging Cell. 12 (3), 370–380 (2013).
Funding
This work was supported in part by the National Institute of Health grants R21 AA029784 and 1R21AG085590-01 (T.K.), RF1 NS082730 (NK) and an Alzheimer’s Association ALZDISCOVERY-1052089 grant (C.M.D.C.). We thank Dr. Adam Grden and Sameer Parashar for their technical assistance.
Author information
Authors and Affiliations
Contributions
Conceptualization: T.K. and C.M.D.C. Methodology: U.S, B.A.C., S.I., Y.A., N.K., Formal Analysis: U.S., T.-H.T., S.I., Visualization: T.-H.T., S.U., C.M.D.C., Supervision: T.K., and C.M.D.C., Writing: T.K., Review and editing: S.U., B.A.C., S.I., Y.A., N.K., T.-H.T., D.S., C.M.D.C., and T.K.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Sabir, U., Csubak, B.A., Ilchenko, S. et al. Sex-specific effects of acetylation on tauopathy in aging htau mice. Sci Rep (2026). https://doi.org/10.1038/s41598-026-41691-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-41691-0
